Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 2,729 Shares of AbbVie Inc. $ABBV

Posted by Francis Steltz on Oct 27th, 2026

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 4.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 58,798 shares of the company’s stock after selling 2,729 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in AbbVie were worth $15,381,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ABBV. Burk Holdings LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at $30,000. Marquette Asset Management LLC boosted its stake in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares in the last quarter. IMG Wealth Management Inc. boosted its stake in AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after acquiring an additional 153 shares in the last quarter. Principia Wealth Advisory LLC boosted its stake in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Tacita Capital Inc acquired a new stake in AbbVie in the second quarter worth $42,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Up 0.4%

Shares of NYSE:ABBV opened at $286.88 on Tuesday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40. The stock’s 50 day moving average is $266.18 and its 200-day moving average is $235.62. The firm has a market capitalization of $506.85 billion, a price-to-earnings ratio of 81.04, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the business earned $2.97 EPS. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s dividend payout ratio is presently 195.48%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research analyst reports. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price target for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. UBS Group upped their price objective on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a report on Tuesday, October 6th. Scotiabank increased their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. HSBC raised their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Oppenheimer boosted their target price on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $279.86.

Check Out Our Latest Stock Report on ABBV

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

AbbVie Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.